This  study  was designed  to investigate  the role  of palliative  gastrectomy  in  advanced gastric adenocarcinoma  patients having hepatic metastasis  without extra-abdominal  disease at diagnosis. Patients  and methods:  This study was performed in  General Surgery Department,  Tanta University  Hospitals,  Egypt  on  29 patients  with  advanced  gastric  cancer  having  hepatic metastasis.  Patients  were selected  with histopathologically proven gastric  adenocarcinoma; presence of hepatic metastasis at the time of diagnosis; absence of extra-abdominal  disease and having  a performance  status of 2 or less  on the Eastern  Cooperative  Oncology  Group (ECOG) scale. None had received  prior  chemotherapy  or radiation  therapy   Patients  were categorized into the two groups; Group I, 8 males and 3 females underwent gastrectomy  with subsequent  chemotherapy   Eighteen patients  in group  II, 11 males  and  7 females received chemotherapy alone without gastrectomy. All patients were treated with systemic 5-jluorouracil based regimens. Results:  The mean  follow-up time  was 258±122  days. The mean  survival of GI and  Gil patients  were 397±59.7 and 173±46.8  days (p > 0.0001).  The mean metastatic  progression­ free survival was 329±54.7  and 141±49.4  days (p > 0.001).  In 11 {38%) of 29 patients  the primary  tumor was removed  (total gastrectomy in 7 and distal gastrectomy  4 patients).  No patient  underwent  liver  resection.  Wound infection  developed  in  one of the patients  of the resection group. He were conservatively treated  One of the patients was reoperated  for minor leakage  from the anastomosis  leading  to intraabdominal collection.  The mean hospital  stay of the first admission for GI and Gil  patients was 13.9 ±6.41 and 4.28±1.41 days respectively (p>O.0001). The Hospitalization index was not different between the two groups. The Ingestion index was significantly higher in GI than in Gil.  Gastrectomy  increased the  survival of the patients regardless to their number and localization of hepatic metastasis. Related risk  factors based on the univariate analysis were serum tumor marker levels (p 0.036), number of hepatic metastasis (p 0.0045), resection of primary tumor (p >0.0001) and the absence of extra hepatic spread (p 0.027). Conclusion: Despite stage IV patients have poor prognosis, removal of the intact  primary tumor  for gastric  cancer with synchronous hepatic metastasis at diagnosis is associated  with improvement in overall survival and metastatic progression-free survival.